Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients

PLoS One. 2020 Nov 11;15(11):e0242184. doi: 10.1371/journal.pone.0242184. eCollection 2020.

Abstract

Ivermectin has recently shown efficacy against SARS-CoV-2 in-vitro. We retrospectively reviewed severe COVID-19 patients receiving standard doses of ivermectin and we compared clinical and microbiological outcomes with a similar group of patients not receiving ivermectin. No differences were found between groups. We recommend the evaluation of high-doses of ivermectin in randomized trials against SARS-CoV-2.

MeSH terms

  • Adult
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Betacoronavirus / isolation & purification
  • COVID-19
  • Coronavirus Infections / diagnosis
  • Coronavirus Infections / drug therapy*
  • Coronavirus Infections / virology
  • Female
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Ivermectin / therapeutic use*
  • Male
  • Middle Aged
  • Nasopharynx / virology
  • Pandemics
  • Pneumonia, Viral / diagnosis
  • Pneumonia, Viral / drug therapy*
  • Pneumonia, Viral / virology
  • Retrospective Studies
  • SARS-CoV-2
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • Immunosuppressive Agents
  • Ivermectin
  • tocilizumab

Supplementary concepts

  • COVID-19 drug treatment

Grant support

The authors received no specific funding for this work.